1

2   DR JYOTHIS THOMAS GEORGE (Orcid ID : 0000-0003-2570-7232)

3

4

9

10

11   **Effect of gonadotropin inhibitory hormone (GnIH) on luteinizing hormone secretion in**
12   **humans.**

13   George JT (1,6), Hendrikse M (2), Veldhuis JD (3), Clarke IJ (4), Anderson RA (1), Millar
14   RP (2, 5)

1. MRC Centre for Reproductive Health, The Queen's Medical Research Institute,
    University of Edinburgh, Edinburgh, UK.
2. Department of Medical Biochemistry and Institute for Infectious Diseases and
    Molecular Medicine, University of Cape Town, Observatory 7925, South Africa.
3. Endocrine Research Unit, Center for Translational Science Activities, Mayo Clinic,
    Rochester, Minnesota, USA.
4. Department of Physiology, School of Biomedical Sciences, Monash University, 13F,
    Clayton, VIC, 3800, Australlia.
5. Mammal Research Institute, and Centre for Neuroendocrinology, University of
    Pretoria, South Africa.
6. Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism,
    Oxford, United Kingdom.

27

28 Abbreviated title: Gonadotropin inhibitory hormone in the human.

29 Precis: Exogenous GnIH decreased LH secretion in post-menopausal women. The stimulation

30 of LH secretion in response to kisspeptin in men was not abrogated by co-administration of

31 GnIH.

32 Corresponding Author

33 Jyothis T George, Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and

34 Metabolism, Oxford, United Kingdom.

35 jyothis.george@nhs.net

40

41 **Abstract**

42 Gonadotropin inhibitory hormone (GnIH, human homologue of RFRP-3) suppresses

43 gonadotropin secretion in animal models, but its effects have not been studied in the human.

44 **Objective**

45 We tested the hypotheses that exogenous GnIH inhibits LH secretion a) in postmenopausal

46 women, and b) in men concurrently administered exogenous kisspeptin.

47 **Design**

48 Following *in vitro* and *in vivo* pre-clinical studies to functionally characterize the GnIH

49 peptide, a dose-finding study (human GnIH 1.5 to 150 μg/kg/h, iv for 3h) was undertaken,

50 and 50 μg/kg/h selected for further evaluation.

51 Five postmenopausal women were administered 50 μg/kg/h iv infusion for 3h or vehicle on

52 two separate days.

53 Four men were administered kisspeptin-10 (0.3 μg/kg iv bolus) with simultaneous infusion of

54 GnIH (50 μg/kg/h, iv for 3h) or vehicle.

55 **Participants.**

56   Healthy postmenopausal women (mean age 58±2 years, LH: 30.8±2.9 IU/L, FSH: 78.7±6.4

57   IU/L, estradiol: <50 pmol/L) and men (39.8±2.1 years, mean total testosterone 12.1±1.8

58   nmol/L, LH 2.2±0.2 IU/L).

59   **Primary Outcome**

60   Change in area-under-curve of LH during GnIH vs. vehicle.

61   **Results**

62   During GnIH administration in postmenopausal women, LH secretion decreased (Δ AUC -

63   9.9±1.8 IU/3h) vs. vehicle (Δ AUC -0.5±1.7 IU/3h) (P= 0.02). Kisspeptin-10 stimulated LH

64   responses in men was not affected by GnIH co-administration (60-min AUC of LH 6.2±0.8

65   IU/h with kisspeptin-10 alone, 6.3±1.0 IU/h, kisspeptin-10 with GnIH, P = 0.72).

66   Exogenous GnIH was well tolerated, with no adverse events reported.

67   **Conclusions.**

68   GnIH decreased LH secretion in postmenopausal women in this first-in-human study.

69   Kisspeptin-stimulated LH secretion in men was not inhibited during concomitant

70   administration of GnIH.

71

72   **Introduction**

73   Pulsatile secretion of gonadotropin releasing hormone (GnRH) stimulates the secretion of

74   gonadotropins (LH and FSH) and the downstream secretion of gonadal steroid hormones.[1-3]

75   Gonadotropin inhibitory hormone (GnIH) is a hypothalamic neuropeptide initially discovered

76   in birds as an inhibitor of LH secretion[4] but its activity has not been studied in humans. We

77   report the first human studies on the effect of exogenous GnIH on LH secretion.

78   The avian GnIH peptide (SIKPSAYLPLRF-NH$_2$) has one human homologue which is

79   inactive and, two orthologues which have the characteristic carboxyl terminal RF-amide.

80   RFRP-1 (MPHSFANLPLRF-NH$_2$) and RFRP-3 (VPNLPQRF-NH$_{2,}$), were isolated and

81   structurally identified in the human hypothalamus.[5] GnIH inhibits GnRH-stimulated

82   mobilization of intracellular calcium in avian[4], ovine[6] and bovine[7] gonadotropes *in vitro* –

83   suggesting a pituitary locus of action. These data, and other evidence from a range of species[5,]

84   [8-14], reviewed recently elsewhere[15], indicate that GnIH is a specific inhibitor of gonadotropin

85   secretion in mammals, signaling through the GnIH receptor (GnIH-R, GPR147) via inhibition

86   of cyclic AMP production. GnIH neurons display close apposition to GnRH neurons in

87 sheep[16] , non-human primate[17] and in human[5] hypothalami, suggesting that GnIH may also

88 directly regulate GnRH secretion.

89 Following pre-clinical studies to characterize the activity of the GnIH peptide *in vitro* and in

90 the ovariectomized ewe, we investigated the effect of GnIH on LH secretion in two human

91 models of increased GnRH secretion: in postmenopausal women, and in in healthy men

92 administered exogenous kisspeptin.

93 **Methods**

94 **GMP kisspeptin and GnIH**

95 Kisspeptin-10 and GnIH peptides were custom synthesized to GMP standards (Bachem

96 GmBH, Weil am Rhein, Germany). Purity was assessed by HPLC at 97% with a mass

97 balance of 98.8%. Both peptides were made up within the hour before injection/infusion by

98 diluting 1 mg of lyophilized peptide in 5 ml sterile normal saline. The bolus dose of

99 kisspeptin-10 (0.3 µg/kg) was selected for acute LH stimulation tests based on our previous

100 dose-finding study of kisspeptin-10 [18] and other published data.[3]

101 **Characterisation of GnIH *in vitro***

102 The objective of these *in vitro* studies was to compare the biological activity of the custom-

103 synthesised GnIH peptide used in the present study with that of GnIH previously used in

104 published data involving non-human species. Whole-cell receptor binding and CRE-luciferase

105 assays were carried out in parallel using the custom-synthesized GMP GnIH and a custom

106 synthesized preparation (EzBiolab, Carmel, IN, USA) used extensively by our laboratory.

107 **Whole-cell receptor binding assay**

108 The methods are described in detail elsewhere[19] but in brief, COS-7 cells were electroporated

109 with 10 µg *NPFFR1 (*GPR147) and seeded in 12 well plates. Forty eight hours post

110 transfection cells were incubated in HEPES-DMEM with 100000 cpm ^{125}I radiolabelled-

111 RFRP3/well and increasing concentrations of non-radiolabelled peptide in the range of 0-

112 1µM for 4 hours at 4°C. Cells were then rapidly washed twice with cold PBS

113 (+MgCl2/CaCl2). Thereafter, 0.5mL 0.1M NaOH was added to the cells and incubated at

114 room temperature for 15 minutes to lyse the cells. Cell lysates were transferred to plastic

115 tubes and bound radioactivity counted with a Berthold LB2111 gamma counter for 1 minute.

116 **CRE-Luciferase Assay**

117 HEK 293T cells were seeded in 24 well plates coated with Matrigel (BD Biosciences). The

118 next day, cells were chemically transfected (X-tremeGENE HP DNA Transfection Reagent

119 (Roche)) with GPR147 and CRE-Luc reporter gene plasmid DNA in a 1:1 DNA ratio. Plates

120　were incubated for 24 hours post transfection and then washed twice with phosphate buffered

121　saline (PBS+). Thereafter, starving media (DMEM [Dulbecco's modified Eagle's medium],

122　1% pen/strep, 4mM L-glutamine, 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid;

123　HEPES) was added to the cells overnight. Media was aspirated and replaced 0.5mL of

124　compound dilutions prepared in starving media. Plates were incubated for 6 hours at 37 °C

125　after which they were transferred to ice and washed with cold PBS+. Diluted passive lysis

126　buffer (20 µL) was added to each well and plates placed on a shaker at 1050 rpm for 15

127　minutes at room temperature. Lysates were diluted 1:4 and 20 µL was transferred to a white,

128　flat bottomed 96 well plate. Luciferase activity was measured for 10 seconds on a Lumat

129　LB9501 Luminometer after 100 µL LARII was added to each well.

LH inhibition by GnIH in ewes

Animals and peptide infusion regime

132　Groups of 4 ovariectomised ewes were held in single pens and both jugular veins were

133　cannulated on the day prior to experimentation to allow blood sampling and infusion. Venous

134　blood samples were taken at 10 min intervals for 7.5 hours, in 2.5 hour blocks, before, during

135　and after infusion of either GnIH or vehicle (saline). The animals received a loading dose of

136　1mg and then an infusion of 1 mg/h, using an infusion rate of 1ml/h. All ovine experiments

137　were carried out at the University of Monash (IJC) in compliance with regulations and ethical

138　standards.

Radioimmunoassay of ovine LH

140　LH in plasma was measured as previously described[20] using NIH-oLH-S18 as the standard

141　and NIDDK-anti-oLH-I as the antiserum. Iodinated ovine LH (125 I-NIDDK-AFD-9598B)

142　was used as tracer. Assay sensitivity was 0.1 ng/ml. Intra-assay coefficient of variation (CV)

143　was <10% between 0.6 and 13.7 ng/ml and inter-assay CV was 7.8% at 10.4 ng/ml and 9.5%

144　at 20.3 ng/ml.[21]

LH Pulse analysis in ovine studies

146　An LH pulse was defined as having occurred when the assay value of a given sample

147　exceeded the assay value of the previous sample by at least 3 standard deviations, as well as

148　other criteria detailed previously[22], using error estimates generated by the computer program

149　of Salamonsen et al.[23] Comparisons of LH pulse amplitude, inter-pulse interval, and mean LH

150　between groups infused with GnIH and vehicle were made using two-way ANOVA.

151

Human studies

Participants

Five healthy postmenopausal women (mean age 58±2 yrs, 12.4±2.6 yrs since last menstrual period, LH: 30.8±2.9 IU/L, FSH: 78.7±6.4 IU/L, estradiol: <50 pmol/L) and four healthy adult men (mean age 39.8±2.1 yrs, total testosterone 12.1±1.8 nmol/L, LH 2.2±0.2 IU/L and FSH 4.8±12 IU/L took part in the study. LH, FSH and testosterone were all within normal range in the men, and this was confirmed on at least one additional morning sample). Baseline physical examination, full blood count, renal function, liver function, and serum electrolytes were within normal limits. All volunteers provided written informed consent to take part in this study, which was approved by the South East Scotland Research Ethics Committee (10/S1101/53). The study was also approved by the Edinburgh Clinical Research Facility Phase 1 and First-in-Human Study Review Committee (Ref E10903).

Peptide infusion protocols for human studies

First, we set to establish a safe and effective dose that achieved nanomolar concentrations of RFRP3 in the peripheral circulation when administered as an intravenous infusion in two post-menopausal women (dose finding study). Second, the effects of the maximally effective dose (identified from the dose-finding study as approximately 50 μg/kg/h) was studied in 3 additional post-menopausal women, to give a total n=5 for this dose. Third, four healthy men were given intravenous boluses of kisspeptin in the presence or absence of GnIH 50 μg/kg/h administered concurrently as intravenous infusion (Kisspeptin-GnIH Study).

Effects of GnIH on LH in post-menopausal women

a) Dose-finding study

The median inhibitory concentration of GnIH at its cognate receptor (GPR147) is 1-2 nM[24]. The objective of this study was therefore to identify a dose at which circulating GnIH concentrations greater than 1 nM were achieved.

Two healthy post-menopausal women were admitted six times to our clinical research facility, with a minimum inter-visit interval of a week. Each of these visits involved six hours of frequent (every 10-min) venous blood sampling to assess effects on LH secretion. After three hours of baseline sampling, an infusion of GnIH (1.5, 5, 15, 50 and 150 μg/kg/h) or vehicle (normal saline) was administered for a further three hours. At the start of this infusion, an intravenous bolus of GnIH (25% of hourly infusion dose) or vehicle was administered, simulating the studies in which GnIH was effective in ovariectomised ewes. For safety reasons, doses were administered in increasing order in an unblinded manner under medical supervision and participants were observed in the research facility for at least an hour

after the infusion completed. <mark>LH sampling was opportunistically continued at 10-min interval during this additional hour of safety monitoring.</mark>

In addition to collection of serum for hormone assays, plasma samples were collected immediately before as well as at regular intervals up to four hours (at 30, 60, 120, 150, 179, 190, 200, 210, 220, 230 and 240 minutes) after commencing the infusion for pharmacokinetic assessment to quantify circulating GnIH. GnIH concentrations were estimated using liquid chromatography tandem mass spectrometry. A DPP-IV inhibitor (Diprotin A, 0.1mM final concentration; Sigma I9759) and protease inhibitor cocktail (Sigma P8340, 1x final concentration; both sourced from Sigma-Aldrich, St. Louis, MO, USA) were added to these samples to inhibit breakdown of GnIH after serum collection.

Blood pressure, pulse rate, and peripheral oxygen saturations were measured with standard automated techniques. Full blood count, serum electrolytes, liver and renal function were checked at the beginning and end of each visit.

b) Effects of 50 μg/kg/h intravenous GnIH in post-menopausal women

<mark>In addition to the two women who participated in dose-finding study, three more healthy postmenopausal women received 50 μg/kg/h intravenous infusions of GnIH</mark> (with a 12.5 μg/kg intravenous bolus at the start of the infusion) and vehicle for three hours each on two separate days, at least a week apart, using the LH sampling protocol outlined above.

LH pulsatility in all five women during the 50 μg/kg/h of GnIH was compared with the pulsatility observed during the infusion of vehicle.

Effects of GnIH on kisspeptn-10 stimulation of LH in healthy men

The objective of this study was to test the hypothesis that co-administration of GnIH would attenuate the stimulatory LH response elicited by kisspeptin.

Healthy male volunteers (n=4) were admitted twice to our clinical research facility for 7.5 hours and LH samples obtained at 10-minute intervals. Two intravenous boluses of kisspeptin-10 (0.3 μg/kg, 23 pmol/kg) were administered at 60-minutes and 270 minutes. On the first visit, an intravenous infusion of saline was started at 240 minutes. <mark>On the second visit, a 50 μg/kg/h intravenous infusion of GnIH was commenced at the identical time-point (240 minutes) to that of vehicle infusion, along with a 12.5 μg/kg intravenous bolus of GnIH administered at the start of this infusion which continued for 180 minutes.</mark> This protocol is identical to the 50 μg/kg/h infusion protocol used in the dose-finding and replication studies described above.

Human LH pulsatility analysis and statistical comparisons

Area-under-curve (AUC) of LH was calculated using trapezoid integration. In studies to assess the impact of exogenous GnIH on LH secretion, 180-min AUC before and during the infusion of GnIH were calculated to derive ΔAUC LH - the arithmetic difference of AUC over three hours before and during the infusion. Paired Student's *t* tests used to compare ΔAUC LH during vehicle and GnIH infusions.

In the kisspeptin-GnIH study, 60-min AUC was calculated during three periods: Baseline (first hour of the study) and 60-min after each of the kisspeptin-10 boluses. Repeated measures ANOVA was used to assess variance in 60-min AUC and multiple comparisons made using Fishers Least Significant Difference (LSD) test. We have previously shown the sensitivity of this approach to detect LH response to kisspeptin-10 [18, 25, 26].

LH pulses were identified and mass-per-pulse (MPP) and basal LH secretion calculated using a deconvolution algorithm using cluster analysis with 93% sensitivity and specificity on blinded data[27]. Paired Student's t test was used to assess changes in pulse frequency, mass-per-pulse and basal LH secretion.

Data are presented as mean±SEM. A two-sided $P<0.05$ was regarded as statistically significant for all analyses. The statistical software package Graphpad Prism 6 for Mac OSX (Graphpad, La Jolla, CA 92037 USA) was used.

Results

In vitro **studies**

GMP custom-synthesised GnIH (Bachem) and comparator peptide (EZbiolab) induced an inhibition of forskolin-induced accumulation of cAMP with similar potencies (Supplementary Fig 1). Both peptides also displayed high affinity for the receptor with no statistically significant difference in the IC50 (data not shown).

In summary, the GnIH peptide used in the present human study thus has identical binding and signalling characterstics to a peptide preparation previously used in non-human studies at the GPR147 receptor.

LH Inhibition by GnIH in Ewes

Infusion of GnIH significantly reduced the amplitude of LH pulses in ovariectomised ewes (Supplementary Fig 2). LH pulse amplitude decreased from 0.9±0.1 ng/ml before the GnIH infusion to 0.4±0 ng/ml during it (P <0.002) and returned to baseline (0.7±0.1 ng/ml) following discontinuation. In the control vehicle infusion group, LH pulse amplitude remained unchanged at 1±0.1 ng/ml before, 1.3±0.2 ng/ml during and 1.3±0.3 ng/ml after infusion.

There were no significant changes in LH pulse frequency or mean LH during either GnIH or vehicle infusions. GnIH infused sheep had 3.8±0.25 pulses before, and 4.0±0 pulses during the infusion, and 4.0±0.4 pulses in the post-infusion study period. Control animals infused with vehicle were observed to have 3.5±0.5, 3.75±0.25 and 3.75±0.5 pulses during corresponding sampling windows.

Individual animal-level data on LH secretion in both GnIH and vehicle treated groups are tabulated in supplementary table 1.

Effects of GnIH on LH in postmenopausal women

Dose finding study

All doses of GnIH were well tolerated, with no adverse events. Both women showed modest but dose-dependant suppression of LH secretion during GnIH infusion. One subject achieved maximal reduction in AUC of LH at 15 μg/kg/h dose (Δ AUC -9.7 IU/L/3h) and the other at 50 μg/kg/h (Δ AUC -10.9 IU/L/3h) (Fig 1A).

During infusion of 50 μg/kg/h, circulating concentrations of GnIH rose from below the limits of quantification (1ng/mL) before administration to 2.4 ±0.4 ng/ml during the infusion (range 1.2-3.8 ng/ml; 1.2-3.9 nM) and 6.5±1.8 ng/ml (range 1.9-11.9 ng/ml; 2-12.3 nM) in the two women. GnIH became undetectable 10 minutes after the end of the infusion.

The highest dose studied (150 μg/kg/h) resulted in higher plasma concentrations of GnIH (10.1±1.5 ng/mL; 10.4±1.5 nM) and (11.1±2.5 ng/mL; 11.5±2.6 nM) in the two subjects. However, this increase in circulating peptide concentration was not associated with larger reductions in LH secretion than that observed with the 50 μg/kg/h dose. Therefore, the lowest dose that achieved nanomolar concentrations in peripheral circulation, i.e. 50 μg/kg/h, was selected for further studies.

LH inhibition by GnIH in post-menopausal women

GnIH infusion (50 μg/kg/h) significantly decreased LH secretion (Δ AUC -9.9±1.8 IU/3h) when compared to the infusion of vehicle (Δ AUC -0.5±1.7 IU/3h) in the five women (*p*=

0.02, Fig 1B). Decreases in mean LH was observed in four out of the five women studied. Individual volunteer-level data on mean LH secretion before, during and after saline and GnIH treatments are tabulated in supplementary table 2.

There was no effect on pulsatile LH secretion (figure 2). Baseline pulse frequency of 0.8±0.1 pulse/h remained unchanged during GnIH treatment, at 0.8±0.1 pulse/h. Nevertheless, mass-per-pulse showed a numerical increase, from 20.2±4.5 IU/l at baseline to 27.8±6.4 IU/l during GnIH infusion (P = 0.052). Consistent with these, the total pulsatile secretion of LH also showed a numerical increase without statistical significance - at 100.6±26.6 IU/L/3h at baseline to 139.1±38.2 IU/L/3h (P = 0.124) during GnIH infusion.

Co-administration of GnIH and kisspeptin-10 in men

Kisspeptin-10 bolus (0.3 µg/kg iv) significantly increased LH secretion, with 60-min AUC of LH increasing from 2.8±0.8 IU/L/h to 6.5±0.9 after each of the two boluses in the control visit. (ANOVA P = 0.005, Fisher's LSD P = 0.003, baseline vs. kisspeptin boluses; 0.96 (comparing the two kisspeptin boluses), Fig 3A.

During concurrent administration of GnIH, both boluses of kisspeptin-10 also elicited significant increases in LH secretion, with 60-min AUC of LH increasing from 3.1±0.5 IU/L/h to 6.2±0.8 IU/L/h with kisspeptin-10 alone vs. 6.3±1.0 IU/L/h with kisspeptin-10 in the presence of GnIH respectively (Fisher's LSD P <0.005). There was no statistical difference between responses to the two kisspeptin-10 boluses administered before or during GnIH infusion (Fisher's LSD P = 0.715), Fig 3B. Individual volunteer-level 60-min AUC during baseline and after the two kisspeptin-10 boluses are tabulated in supplementary table 3. Figure 4 provides exemplar LH profiles from a participant during GnIH and vehicle infusion visits.

Safety of GnIH

GnIH infusions were well tolerated with no serious adverse events reported. Heart rate and blood pressure, which were monitored intensely during study visits, showed no significant change. Serum electrolytes, renal function, full blood count and liver function monitored at all study visits also remained unchanged.

Discussion

The present study provides first-in-human data on the effects of exogenous GnIH effects on LH secretion in women and men, in paradigms of increased GnRH secretion. In postmenopausal women, GnIH administration resulted in a modest suppression of LH secretion, while it did not affect kisspeptin-stimulated LH secretion in men. GnIH was well

tolerated by men and women who took part in this first in man study, providing reassurance about its safety for future clinical studies.

Infusions of GnIH (up to the dose of 150 μg/kg/h in two post-menopausal women, 50 μg/kg/h in all other men and women) for three hours were well tolerated. Serum concentrations in the low nanomolar range were achieved with continuous intravenous infusion of GnIH at 50 μg/kg/h and associated with significant decrease in LH secretion (AUC of LH) in post-menopausal women. We demonstrated that the circulating concentrations of 1.2-12.3 nM/L achieved are sufficient to bind to the GPR147 receptor and inhibit forskolin-stimulated cAMP generation (Fig 1).

Our results are consistent with decreased LH secretion observed in large animal models (ewes and calves) exposed to GnIH.[6, 7] In rodents, the effects of GnIH appear to show sexual dimorphism. Male rats[9, 14] and hamsters[8] respond with gonadotropin suppression, while female rats showed no change in LH or FSH when the peptide was administered intracerebroventricularly. [28]

The pattern of reduction in LH secretion observed in post menopausal women in our study during GnIH administration appears to be broadly concordant with that observed in previously published ovine[6] and bovine models[7]. Post-menopausal women in the present study showed no change in LH pulse frequency; the corresponding ovine model (ovariectomised sheep) also showed no reduction in pulse frequency in the present study as well as in previous studies.[6] A previous study using a bovine model did show a reduction in pulse frequency[7] but in that study GnIH was administered as multiple boluses rather than by infusion. Furthermore, the bovine models used were castrated males, which does not allow direct comparison with the data in the present study.

The magnitude of reduction of LH in human volunteers in the present study appears to be lower than the marked reduction in serum LH observed in ovariectomised sheep.[6] There is considerable inter-species difference in the effects of GnIH[29], which may explain some of the differences. Therefore, the most parsimonious explanation for the differential responses in ovine models and human volunteers is potential inter-species variability. Furthermore, as our study was based only on a small number of participants, the true effect size of LH response to GnIH in a wider population cannot be reliably extrapolated. In addition, administration of exogenous peptide hormones, i.e., the experimental paradigm employed here, is not an appropriate technique to study the physiological role of the peptide. However, even when taking study limitations into consideration, the limited suppression of LH observed in the present study suggests that pharmacological application of GnIH (or its agonists) in human disorders of excess LH secretion may not be feasible.

351   GnIH had no effect on kisspeptin-stimulated LH secretion in men in the present study where

352   50 μg/kg/h was administered as continuous intravenous infusion. In addition to its main

353   objectives, the present study also assessed the effects of repeated doses of kisspeptin-10

354   boluses within the same individual – four boluses on two separate study days. These data

355   showed that there was remarkable intra-individual consistency in LH response to kisspeptin-

356   10 (supplemental table 3). This is distinct from the tachyphylaxis observed on repeated dosing

357   of kisspeptin-54[3] or with longer-acting kisspeptin analogues.[30] This finding could lend

358   support for the continuing development of kisspeptin-10 as a physiologic probe to ascertain

359   GnRH function *in* or as a potential therapeutic option to stimulate GnRH endogenously.[3]

360   We chose kisspeptin-10 administration as a model of LH stimulation to study the effects of

361   GnIH on LH secretion in men. Kisspeptin acts via endogenous GnRH secretion and results in

362   a doubling in peripheral LH concentrations, comparable to an endogenous LH pulse, and is

363   thus a more physiologically relevant stimulus than exogenous GnRH, which elicits around a

364   10-fold rise in LH.[3] Furthermore, we have previously shown that the acute LH-response to

365   kisspeptin in men is not affected by prevailing sex-steroid status.[25] LH response to kisspeptin

366   remained unchanged with concurrent administration of GnIH.

367   With the limited LH suppression observed in these first-in-man studies in both men and

368   women, it is reasonable to speculate that the role of GnIH in the regulation of LH secretion in

369   the human may be less robust than in other species. Nevertheless these studies have

370   limitations. As a first-in-human study with associated safety considerations, the exposure to

371   human volunteers in the study was limited to 3 hours and only a small number of volunteers

372   were studied. Furthermore, we did not undertake a separate dose-finding study in men, but

373   have assumed similar pharmacokinetics in men and women.

374   GnRH-induced gonadotropin subunit gene transcription is suppressed by GnIH orthologues

375   by inhibiting adenylate cyclase/cAMP/protein kinase A-dependent ERK activation.[31] This

376   transcriptional effect suggests that a longer exposure paradigm may have achieved greater

377   suppression of LH secretion. However, the rapid clearance of GnIH from circulation observed

378   here makes it challenging to deliver sufficient quantities of the native peptide intravenously to

379   maintain stable serum concentrations over long durations. This challenge has been effectively

380   overcome for GnRH and other small peptide hormones by incorporation of D-amino acids to

381   reduce proteolytic degradation and by formulating in biodegradable polymers which can

382   deliver efficacious levels of peptide for up to one year. Therapeutic potential of GnIH to treat

383   disorders characterised by increased LH secretion (e.g. PCOS, menopausal hot flushes,

384   precocious puberty) needs to be assessed in context of emerging data on kisspeptin and

385 <mark>neurokinin B modulation. Prima facie, GnIH appears to be a less potent tool in comparison to</mark>
386 <mark>these approaches.</mark>[3, 32]

387 In conclusion, in this first-in-human study, we have demonstrated that exogenously
388 administered GnIH has a suppressive effect on LH secretion in postmenopausal women and
389 that kisspeptin-10 mediated LH secretion in men is <mark>unaffected</mark> during concomitant
390 administration of GnIH. Further studies, are required to fully elucidate the physiological
391 mechanisms and the therapeutic potential for GnIH.

392 **Author Contributions**

393 RPM conceived the study, JTG developed the study protocol and managed the study, guided
394 by RPM, RAA and RW. JTG supervised the administration of all doses of GnIH, collated
395 biochemical results and wrote the first draft of this manuscript. Deconvolution analysis of LH
396 pulsatility was carried out by JDV on blinded data. IJC designed, supervised and reported the
397 ovine studies of GnIH. MG carried out *in vitro* studies. All authors contributed to the revision
398 of this manuscript and have approved the final version.

399

400 **Figure 1:** Reductions in 180-minute Area-under-curve (ΔAUC) of Luteinising Hormone in
401 postmenopausal women administered GnIH. **A**, ΔAUC of LH in two postmenopausal women
402 administered vehicle and GnIH infusions at 1.5, 5, 15, 50 and 150 μg/kg/h. Each of the data
403 series represents data from an individual volunteer. Each series represents a single woman
404 receiving all five doses and vehicle. One subject only had 0.07 unit decrease. **B**, ΔAUC of
405 LH in five postmenopausal women administered vehicle (white column) and RFPR-3
406 infusion at 50 μg/kg/h (black column). The data include those of the 50 μg/kg/h from the two
407 women receiving the various doses (**1A** above) and four additional women (* P=*0.02*)

408 **1A**

409

410

411 **1B**

412

413

414 **Figure 2:** LH pulse profiles of five postmenopausal women administered 50 mcg/kg/hour
415 GnIH (red squares) and saline infusions (blue triangles). Blood samples were drawn at 10-min
416 intervals throughout the study. Intravenous infusion of GnIH was maintained for three hours,
417 from 0 to 180 min, and an intravenous bolus of GnIH (12.5 μg/kg) was administered at time
418 0.

419
420

Figure 3. LH secretion (60 minute AUC, IU/h) at baseline and during the hour after healthy men were administered boluses of kisspeptin-10 (0.3 μg/kg). Co-administration of vehicle (A) or GnIH (B) did not impact on the stimulatory effect of kisspeptin on LH secretion. * p <0.05.

424

425

426

427

Figure 4: LH pulse profiles of one of the male volunteers on the two days when vehicle
(squares) and GnIH (circles) were administered for three hours - from 0 min to 180 min.
Patients had one hour of LH profiling at the beginning of each session to quantify baseline
LH secretion (-240 to -180 min). Kisspeptin was administered at -180 and +30 mins during
both these study visits, to quantify 60-min area-under-curve of LH following each of these.

433

434

References

1   Millar, R.P. (2005) GnRHs and GnRH receptors. *Animal Reproduction Science* **88**, 5-
28.

438   2   Balasubramanian, R., Dwyer, A., Seminara, S.B., Pitteloud, N., Kaiser, U.B. & Crowley,

439   J.W.F. (2010) Human GnRH Deficiency: A Unique Disease Model to Unravel the Ontogeny of

440   GnRH Neurons. *Neuroendocrinology*, 81-99.

441   3   Skorupskaite, K., George, J.T. & Anderson, R.A. (2014) The kisspeptin-GnRH pathway

442   in human reproductive health and disease. *Human Reproduction Update* **20**, 485-500.

443   4   Tsutsui, K., Saigoh, E., Ukena, K., Teranishi, H., Fujisawa, Y., Kikuchi, M., Ishii, S. &

444   Sharp, P.J. (2000) A Novel Avian Hypothalamic Peptide Inhibiting Gonadotropin Release.

445   *Biochemical and Biophysical Research Communications* **275**, 661-667.

446   5   Ubuka, T., Morgan, K., Pawson, A.J., Osugi, T., Chowdhury, V.S., Minakata, H.,

447   Tsutsui, K., Millar, R.P. & Bentley, G.E. (2009) Identification of Human GnIH Homologs, RFRP-

448   1 and RFRP-3, and the Cognate Receptor, GPR147 in the Human Hypothalamic Pituitary Axis.

449   *PLoS ONE* **4**, e8400.

450   6   Clarke, I.J., Sari, I.P., Qi, Y., Smith, J.T., Parkington, H.C., Ubuka, T., Iqbal, J., Li, Q.,

451   Tilbrook, A., Morgan, K., Pawson, A.J., Tsutsui, K., Millar, R.P. & Bentley, G.E. (2008) Potent

452   Action of RFamide-Related Peptide-3 on Pituitary Gonadotropes Indicative of a

453   Hypophysiotropic Role in the Negative Regulation of Gonadotropin Secretion. *Endocrinology*

454   **149**, 5811-5821.

455   7   Kadokawa, H., Shibata, M., Tanaka, Y., Kojima, T., Matsumoto, K., Oshima, K. &

456   Yamamoto, N. (2009) Bovine C-terminal octapeptide of RFamide-related peptide-3

457   suppresses luteinizing hormone (LH) secretion from the pituitary as well as pulsatile LH

458   secretion in bovines. *Domestic Animal Endocrinology* **36**, 219-224.

459   8   Kriegsfeld, L.J., Mei, D.F., Bentley, G.E., Ubuka, T., Mason, A.O., Inoue, K., Ukena, K.,

460   Tsutsui, K. & Silver, R. (2006) Identification and characterization of a gonadotropin-inhibitory

461   system in the brains of mammals. *Proceedings of the National Academy of Sciences of the*

462   *United States of America* **103**, 2410-2415.

463   9   Johnson, M.A., Tsutsui, K. & Fraley, G.S. (2007) Rat RFamide-related peptide-3

464   stimulates GH secretion, inhibits LH secretion, and has variable effects on sex behavior in the

465   adult male rat. *Hormones and Behavior* **51**, 171-180.

466   10   Gibson, E.M., Humber, S.A., Jain, S., Williams, W.P., Zhao, S., Bentley, G.E., Tsutsui, K.

467   & Kriegsfeld, L.J. (2008) Alterations in RFamide-Related Peptide Expression Are Coordinated

468   with the Preovulatory Luteinizing Hormone Surge. *Endocrinology* **149**, 4958-4969.

469   11   Murakami, M., Matsuzaki, T., Iwasa, T., Yasui, T., Irahara, M., Osugi, T. & Tsutsui, K.

470   (2008) Hypophysiotropic role of RFamide-related peptide-3 in the inhibition of LH secretion

471   in female rats. *Journal of Endocrinology* **199**, 105-112.

472 12 Sari, I.P., Rao, A., Smith, J.T., Tilbrook, A.J. & Clarke, I.J. (2009) Effect of RF-Amide-

473 Related Peptide-3 on Luteinizing Hormone and Follicle-Stimulating Hormone Synthesis and

474 Secretion in Ovine Pituitary Gonadotropes. *Endocrinology* **150**, 5549-5556.

475 13 Ubuka, T., Inoue, K., Fukuda, Y., Mizuno, T., Ukena, K., Kriegsfeld, L.J. & Tsutsui, K.

476 (2012) Identification, Expression, and Physiological Functions of Siberian Hamster

477 Gonadotropin-Inhibitory Hormone. *Endocrinology* **153**, 373-385.

478 14 Pineda, R., Garcia-Galiano, D., Sanchez-Garrido, M.A., Romero, M., Ruiz-Pino, F.,

479 Aguilar, E., Dijcks, F.A., Blomenr√∂hr, M., Pinilla, L., van Noort, P.I. & Tena-Sempere, M.

480 (2010) Characterization of the inhibitory roles of RFRP3, the mammalian ortholog of GnIH, in

481 the control of gonadotropin secretion in the rat: in vivo and in vitro studies. *American*

482 *Journal of Physiology - Endocrinology And Metabolism* **299**, E39-E46.

483 15 Kriegsfeld, L.J., Ubuka, T., Bentley, G.E. & Tsutsui, K. (2015) Seasonal control of

484 gonadotropin-inhibitory hormone (GnIH) in birds and mammals. *Frontiers in*

485 *Neuroendocrinology* **37**, 65-75.

486 16 Smith, J.T., Coolen, L.M., Kriegsfeld, L.J., Sari, I.P., Jaafarzadehshirazi, M.R., Maltby,

487 M., Bateman, K., Goodman, R.L., Tilbrook, A.J., Ubuka, T., Bentley, G.E., Clarke, I.J. &

488 Lehman, M.N. (2008) Variation in Kisspeptin and RFamide-Related Peptide (RFRP) Expression

489 and Terminal Connections to Gonadotropin-Releasing Hormone Neurons in the Brain: A

490 Novel Medium for Seasonal Breeding in the Sheep. *Endocrinology* **149**, 5770-5782.

491 17 Smith, J.T., Shahab, M., Pereira, A., Pau, K.-Y.F. & Clarke, I.J. (2010) Hypothalamic

492 Expression of KISS1 and Gonadotropin Inhibitory Hormone Genes During the Menstrual

493 Cycle of a Non-Human Primate. *Biology of Reproduction* **83**, 568-577.

494 18 George, J.T., Veldhuis, J.D., Roseweir, A.K., Newton, C.L., Faccenda, E., Millar, R.P. &

495 Anderson, R.A. (2011) Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse

496 Frequency in Men. *Journal of Clinical Endocrinology & Metabolism* **96**, E1228-E1236.

497 19 Flanagan, C.A., Fromme, B.J., Davidson, J.S. & Millar, R.P. (1998) A High Affinity

498 Gonadotropin-Releasing Hormone (GnRH) Tracer, Radioiodinated at Position 6, Facilitates

499 Analysis of Mutant GnRH Receptors. *Endocrinology* **139**, 4115-4119.

500 20 Lee, V.W.K., Cumming, I.A., de Kretser, D.M., Findlay, J.K., Hudson, B. & Keogh, E.J.

501 (1976) Regulation of gonadotrophin secretion in rams from birth to sexual maturity. *Journal*

502 *of Reproduction and Fertility* **46**, 1-6.

503 21 CLARKE, I.J. & CUMMINS, J.T. (1985) Increased Gonadotropin-Releasing Hormone

504 Pulse Frequency Associated with Estrogen-Induced Luteinizing Hormone Surges in

505 Ovariectomized Ewes. *Endocrinology* **116**, 2376-2383.

506   22   Clarke, I.J. (1993) Variable patterns of gonadotropin-releasing hormone secretion

507   during the estrogen-induced luteinizing hormone surge in ovariectomized ewes.

508   *Endocrinology* **133**, 1624-1632.

509   23   Salamonsen, L.A., Burger, H.G., Chamley, W.A. & Goding, J.R. (1972)

510   Radioimmunoassay for ovine FSH. *J Reprod Fertil* **28**, 131-132.

511   24   Yoshida, H., Habata, Y., Hosoya, M., Kawamata, Y., Kitada, C. & Hinuma, S. (2003)

512   Molecular properties of endogenous RFamide-related peptide-3 and its interaction with

513   receptors. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research* **1593**, 151-157.

514   25   George, J.T., Veldhuis, J.D., Tena-Sempere, M., Millar, R.P. & Anderson, R.A. (2013)

515   Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: Kisspeptin-10

516   stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild

517   biochemical hypogonadism. *Clinical Endocrinology* **79**, 100-104.

518   26   George, J.T., Anderson, R.A. & Millar, R.P. (2012) Kisspeptin-10 stimulation of

519   gonadotrophin secretion in women is modulated by sex steroid feedback. *Human*

520   *Reproduction* **27**, 3552-3559.

521   27   Liu, P.Y., Keenan, D.M., Kok, P., Padmanabhan, V., O'Byrne, K.T. & Veldhuis, J.D.

522   (2009) Sensitivity and specificity of pulse detection using a new deconvolution method. *Am J*

523   *Physiol Endocrinol Metab* **297**, E538-544.

524   28   Anderson, G.M., Relf, H.-L., Rizwan, M.Z. & Evans, J.J. (2009) Central and Peripheral

525   Effects of RFamide-Related Peptide-3 on Luteinizing Hormone and Prolactin Secretion in

526   Rats. *Endocrinology* **150**, 1834-1840.

527   29   Tsutsui, K., Ubuka, T., Bentley, G.E. & Kriegsfeld, L. (2013) Review: Regulatory

528   mechanisms of gonadotropin-inhibitory hormone (GnIH) synthesis and release in

529   photoperiodic animals. *Frontiers in Neuroscience* **7**.

530   30   MacLean, D.B., Matsui, H., Suri, A., Neuwirth, R. & Colombel, M. (2014) Sustained

531   Exposure to the Investigational Kisspeptin Analog, TAK-448, Down-Regulates Testosterone

532   into the Castration Range in Healthy Males and in Patients With Prostate Cancer: Results

533   From Two Phase 1 Studies. *The Journal of Clinical Endocrinology & Metabolism* **99**, E1445-

534   E1453.

535   31   Son, Y.L., Ubuka, T., Millar, R.P., Kanasaki, H. & Tsutsui, K. (2012) Gonadotropin-

536   Inhibitory Hormone Inhibits GnRH-Induced Gonadotropin Subunit Gene Transcriptions by

537   Inhibiting AC/cAMP/PKA-Dependent ERK Pathway in LŒ≤T2 Cells. *Endocrinology* **153**, 2332-

538   2343.

539   32   George, J.T., Kakkar, R., Marshall, J., Scott, M.L., Finkelman, R.D., Ho, T.W., Veldhuis,

540   J., Skorupskaite, K., Anderson, R.A., McIntosh, S. & Webber, L. (2016) Neurokinin B Receptor

541   Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled

542   Trial. *The Journal of Clinical Endocrinology & Metabolism* **101**, 4313-4321.

543

544

Supplementary data

546

		Mean LH (IU)	Number of Pulses	Pulse Amplitude (IU)	IPI (Min)
Sheep 1	Prior to infusion	1.85	3	1.34	36.7
	During infusion	2.6	4	1.94	43.3
	After infusion	2.74	3	2.07	50
Sheep 2	Prior to infusion	3.67	3	3.36	36.7
	During infusion	3.68	4	4.59	42.5
	After infusion	3.93	4	3.31	42.5
Sheep 3	Prior to infusion	1.17	4	0.74	35
	During infusion	1.38	4	0.53	37.5
	After infusion	1.39	5	0.43	32
Sheep 4	Prior to infusion	2.66	3	2.1	40
	During infusion	2.83	4	2.9	42.5
	After infusion	2.98	3	4.72	43.3

Sheep 5	Prior to infusion	2.71	4	2.12	35
	During infusion	2.36	4	0.89	40
	After infusion	3.33	3	6.74	43.3
Sheep 6	Prior to infusion	2.79	4	1.53	35
	During infusion	3.31	4	1.89	40
	After infusion	3.38	4	2.31	40
Sheep 7	Prior to infusion	1.74	5	1.61	30
	During infusion	1.97	4	1.96	35
	After infusion	1.86	5	1.01	34
Sheep 8	Prior to infusion	3.5	3	2.94	46.7
	During infusion	3.89	3	2.43	43.3
	After infusion	3.95	4	2.21	42.5

547 **Supplementary table 1:** LH secretory parameters (mean LH, pulse frequency, pulse

548 amplitude and inter-pulse interval (IPI) in ovariectomised sheep administered GnIH (1mg/hr)

549 or vehicle. Sheep 1, 4 , 7 and 8 were controls to sheep 2,3, 5 and 6 receiving GnIH.

550

		Mean LH (IU/L) Saline administration	Mean LH (IU/L) GnIH administration
Subject 1	Prior to infusion	21.8±0.9	20.4±0.5
	During infusion	22.8±0.7	17.7±0.4

	After infusion	24.5±0.7	20.1±0.4
Subject 2	Prior to infusion	26.0±0.5	26.7±0.6
	During infusion	28.3±0.5	26.7±0.9
	After infusion	27.3±0.5	28.6±0.9
Subject 3	Prior to infusion	33.1±0.3	28.4±0.2
	During infusion	33.3±0.3	27.8±0.3
	After infusion	32.6±0.3	27.8±0.3
Subject 4	Prior to infusion	40.3±0.9	42.4±1.0
	During infusion	40.0±0.6	38.8±1.0
	After infusion	39.2±0.6	36.7±1.0
Subject 5	Prior to infusion	25.4±0.5	23.0±0.6
	During infusion	23.4±0.4	21.6±0.5
	After infusion	N/A	19.0±0.5

551

Supplementary table 2: Mean LH concentrations in five post menopausal women administered GnIH (50 mcg/kg) or saline infusions for 180 min. Data expressed as Mean ±SEM of peripheral LH concentrations obtained at 10-min intervals for the 180 minutes preceding and 60 minutes following infusion.

556

	Saline administration visit			GnIH administration visit		
	60-min AUC Baseline	60-min AUC after first kisspeptin bolus	60-min AUC after second kisspeptin bolus	60-min AUC Baseline	60-min AUC after first kisspeptin bolus	60-min AUC after second kisspeptin bolus
Subject 1	2.0	8.1	8.4	3.7	7.4	8.4
Subject 2	5.1	6.8	6.9	3.4	6.5	6.4
Subject 3	2.8	6.9	6.6	3.6	7.0	6.8
Subject 4	1.3	4.1	4.2	1.8	3.8	3.7

557

558 **Supplementary table 3:** Area-Under-Curve (IU/hr) in four male volunteers administered

559 GnIH or saline infusions concurrently with kisspeptin-10 boluses. Increase in AUC after first

560 kisspeptin-10 bolus indicates the stimulatory effect of kisspeptin-10 (0.3mcg/kg) on its own.

561 The second bolus was administered concurrently with GnIH (50mcg/kg) or normal saline.

562 AUCs following these second boluses of kisspeptin-10 were comparable to the first,

563 suggesting a lack of modulatory effect of GnIH on kisspeptin-stimulated LH release.

564 **Supplementary Figures**

565

566

567

568

569 **Supplementary Figure 1:** *In vitro* comparsion of biological activity of the custom-
570 synthesised GMP grade human GnIH used in the present study with that of GnIH previously
571 used in published data involving non-human species. Both peptides induced an inhibition of
572 forskolin-induced accumulation of cAMP with similar potencies. RLU= relative luciferase
573 units. N=3.

574

575

576

577

578

579

580 **Supplementary Figure 2**: LH pulse amplitude before (B), during (D) and after (A) vehicle or
581 GnIH (1mg/hr) infusions in ovariectomised ewes (n=4) each. Significant reduction in the
582 amplitude of LH pulses (ANOVA p<0.002) was observed during GnIH infusion.